Valion Bio, Inc. (VBIO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Valion Bio, Inc. (VBIO) closed at USD 1.45 on 2026-10-14, a change of -97.8 % over the past year, with a market capitalization of USD 2.39M.

Valion Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Valion Bio, Inc. key figures

Previous close

USD 1.45 (2026-10-14)

1-year change

-97.8 %

Market cap

USD 2.39M

Enterprise value

USD 16.39M

P/E ratio (trailing)

-0.01

P/E ratio (forward)

n/a

EPS (trailing)

-141.18

EPS (forward)

n/a

PEG ratio

n/a

Price to book

0.05

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.03

Employees

52

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Valion Bio, Inc.

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Valion Bio, Inc. and compare it with other stocks.